Boulder, CO – According to filings with the U.S. Securities and Exchange Commission, DMC Biotechnologies is raising $43,500,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Matthew Lipscomb played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About DMC Biotechnologies
DMC is a privately-held company, producing bio-based chemicals using fermentation. Many chemicals are too expensive today for broad market adoption, such as certain amino acids for animal feed or natural cleaning agents for personal care. These products can be made more affordably and reliably using our technology. We believe in sustainability and economic viability. Our patented technology makes products with lower energy and resource use, with applications that can contribute to a more sustainable economy.

To learn more about DMC Biotechnologies, visit http://dmcbio.com/

Contact:
Matthew Lipscomb, Chief Executive Officer
720-239-7239
matt@dmcbio.com
https://www.linkedin.com/in/matt-lipscomb-325bba25/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved